Mylan defeats Sanofi’s claims it illegally prevented competition to EpiPen
Sanofi-Aventis failed to demonstrate that Mylan monopolised the market for epinephrine auto-injectors used to treat severe allergic reactions, a Kansas federal court ruled in a recently unsealed opinion.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10